Log in to search using one of your social media accounts:

 

FDA approves first drug for the 'Jolie gene'

The Food and Drug Administration  on Friday approved AstraZeneca PLC's Lynparza for patients with BRCA gene mutations who have undergone chemotherapy.
Source: the Mail online | Health - Category: Consumer Health News Source Type: news

Related Links:

ConclusionThe FOLFOXIRI + panitumumab chemotherapy regimen was well tolerated by our patients with mCRC and showed promising anti-tumor activity. The recommended phase II dose was determined to be the same as the standard doses of this regimen used worldwide.
Source: International Journal of Clinical Oncology - Category: Cancer & Oncology Source Type: research
AbstractPurposeWe investigated prospectively whether18F-2-fluoro-2-deoxyglucose positron emission tomography/computed tomography (FDG PET/CT) can predict the overall survival (OS) of patients with advanced renal cell carcinoma (RCC) previously treated by molecular targeted therapies.MethodsBetween 2009 and 2016, 81 patients who had received single molecular targeted therapies (43 sorafenib, 27 sunitinib, 8 temsirolimus and others) and were scheduled for second line molecular targeted therapies for advanced RCC were enrolled in this prospective study. FDG PET/CT was performed after first line molecular targeted therapies, t...
Source: Cancer Chemotherapy and Pharmacology - Category: Cancer & Oncology Source Type: research
ConclusionHere, we discuss the evidence for the use of PARPi as single-agent therapeutics and maintenance treatment in HGSOC and evaluate the genetic assays used in clinical trials so far. We discuss the emerging role of platinum sensitivity as a broad eligibility criteria for the use of PARPi.
Source: Cancer Chemotherapy and Pharmacology - Category: Cancer & Oncology Source Type: research
A randomized, placebo-controlled pilot trial of aprepitant combined with standard antiemetic therapy for the prevention of chemotherapy-induced nausea and vomiting in patients undergoing cyclophosphamide-based conditioning regimens prior to hematopoietic stem cell transplant (HSCT), Published online: 20 February 2018; doi:10.1038/s41409-018-0106-8A randomized, placebo-controlled pilot trial of aprepitant combined with standard antiemetic therapy for the prevention of chemotherapy-induced nausea and vomiting in patients undergoing cyclophosphamide-based conditioning regimens prior to hematopoietic stem cell transplant (HSCT)
Source: Bone Marrow Transplantation - Category: Hematology Authors: Source Type: research
We present the case of a soft tissue, fungating tumor of 15 years' duration of the medial ankle in an 85-year-old male that exhibited malignant features clinically and radiographically. Subsequent punch biopsy revealed a diagnosis of malignant hidradenocarcinoma. Given the risk of recurrence and the poor radiation and chemotherapy options, the patient initially decided to leave the lesion untreated. However, he soon developed lower extremity cellulitis from the exposed lesion and decided to have the tumor excised, eliminating the source of the infection. In the present case study, we discuss the etiology, clinical and radi...
Source: The Journal of Foot and Ankle Surgery - Category: Orthopaedics Source Type: research
Dalton Trans., 2018, Advance Article DOI: 10.1039/C7DT04093H, PaperArif Gulzar, Jiating Xu, Liangge Xu, Piaoping Yang, Fei He, Dan Yang, Guanghui An, Mohd Bismillah Ansari The disulfide bond (-S-S-) is an enormously valuable functional group in a variety of chemical and biological agents that display effective reactivity or biological activities (e.g., antitumor activities). To cite this article before page numbers are assigned, use the DOI form of citation above. The content of this RSS Feed (c) The Royal Society of Chemistry
Source: RSC - Dalton Trans. latest articles - Category: Chemistry Authors: Source Type: research
Memorial Sloan Kettering Cancer Center in New York City has opened a clinical trial for mesothelioma involving a combination of targeted radiation and the novel immunotherapy drug avelumab. Hopes are high for the first-of-its kind study. The trial will be conducted at Memorial Sloan Kettering’s main campus and regional sites. It is open to pleural and peritoneal mesothelioma patients. Radiation oncologist Dr. Andreas Rimner and medical oncologist Dr. Marjorie Zauderer are the lead investigators of the trial, which is expected to run through 2020. Avelumab is designed to block a specific protein (PD-L1) found on the...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Tags: avelumab Chris Boshoff Dr. Andreas Rimner Dr. Kenneth Rosenzweig Dr. Marjorie Zauderer Dr. Raffit Hassan immunotherapy for mesothelioma immunotherapy radiation combination mesothelioma Memorial Sloan Kettering Cancer Center mesothelioma Source Type: news
Conclusion:Use of amitriptyline mouthwash had local anesthetic effects in oral mucositis without systemic side effects. Decrease in the severity of pain with the use of amitriptyline mouthwash was more than that of benzydamine HCL mouthwash. Keywords●Amitriptyline  ●Benzydamine Mucositis  ●Topical anesthetic  ●Mouthwash
Source: Journal of Dentistry, Shiraz University of Medical Sciences - Category: Dentistry Source Type: research
Following the completion of the initial stages of the KEYNOTE-045 trial of pembrolizumab vs. the standard care for advanced urothelial cancer following chemotherapy (NCT02256436), clinicians have been... Author: VJOncology Added: 02/19/2018
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts
The UK was well represented at the Genitourinary Cancers Symposium 2018, held in San Francisco, CA. In this video, Robert Jones, PhD, of the University of Glasgow & Beatson West of Scotland Cancer... Author: VJOncology Added: 02/19/2018
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts
More News: AstraZeneca | Chemotherapy | Food and Drug Administration (FDA) | Genetics | Health